NeoGenomics, Inc. completed an offering of $316.25 million in 0.75% Convertible Senior Notes due 2032, which included an additional $41.25 million in notes. The company also entered into capped call transactions to reduce potential dilution, costing approximately $28.7 million. Concurrently, the company repurchased approximately $276.0 million of its existing 0.25% convertible senior notes due 2028 for a total cost of $263.19 million. NeoGenomics, Inc. is a healthcare company providing oncology-focused diagnostic services.
